scholarly journals 57PD Multicenter observational study of fulvestrant 500 mg in postmenopausal Japanese women with ER positive advanced or recurrent breast cancer after prior endocrine treatment (SBCCSG29 study)

2015 ◽  
Vol 26 ◽  
pp. ix16
Author(s):  
K. Kimizuka ◽  
K. Inoue ◽  
S. Nagai ◽  
T. Saito ◽  
S. Nakano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Recurrent Breast Cancer ◽  
Japanese Women ◽  
Endocrine Treatment ◽  
Multicenter Observational Study ◽  
Er Positive ◽  
Recurrent Breast

HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study

2007 ◽  
Vol 25 (6) ◽  
pp. 662-668 ◽  
Author(s):  
Maurice P.H.M. Jansen ◽  
Anieta M. Sieuwerts ◽  
Maxime P. Look ◽  
Kirsten Ritstier ◽  
Marion E. Meijer-van Gelder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Recurrent Breast Cancer ◽  
Tamoxifen Therapy ◽  
Tumor Aggressiveness ◽  
Expression Ratio ◽  
Free Survival ◽  
Expression Levels ◽  
Er Positive ◽  
Recurrent Breast

Purpose A HOXB13-to-IL17BR expression ratio was previously identified to predict clinical outcome of breast cancer patients treated with adjuvant tamoxifen. However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both. Patients and Methods We have measured the HOXB13 and IL17BR expression levels by real-time polymerase chain reaction in 1,252 primary breast tumor specimens. Expression levels were normalized to housekeeper gene levels and related to clinicopathologic factors for all patients. The primary objective of this study was to determine the relationship of a HOXB13-to-IL17BR ratio with tumor aggressiveness and/or with response to tamoxifen therapy in estrogen receptor (ER) -positive disease. We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193). The odds ratio (OR) and hazard ratio (HR) and their 95% CI were calculated, and all P values were two-sided. Results The HOXB13-to-IL17BR ratio was significantly associated with DFS and PFS. In multivariate analysis, HOXB13-to-IL17BR ratio expression levels were associated with a shorter DFS for node-negative patients only. Corrected for traditional predictive factors, the dichotomized HOXB13-to-IL17BR ratio was the strongest predictor in multivariate analysis for a poor response to tamoxifen therapy (OR = 0.16; 95% CI, 0.06 to 0.45; P < .001) and a shorter PFS (HR = 2.97; 95% CI, 1.82 to 4.86; P < .001). Conclusion High HOXB13-to-IL17BR ratio expression levels associate with both tumor aggressiveness and tamoxifen therapy failure.

A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 588-588 ◽  
Author(s):  
Reiki Nishimura ◽  
Keisei Anan ◽  
Yutaka Yamamoto ◽  
Kenji Higaki ◽  
Maki Tanaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Aromatase Inhibitor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Breast Cancer ◽  
Endocrine Treatment ◽  
Premenopausal Patients ◽  
Recurrent Breast ◽  
Lh Rh

588 Background: The aim was to provide an endocrine therapy option against advanced (ABC) or recurrent breast cancer (RBC) in premenopausal women. We conducted an exploratory phase II trial in combination with an LH-RH analogue (LH-RHa) and an aromatase inhibitor (AI) to assess the efficacy and tolerability after failure of standard LH-RHa plus tamoxifen (TAM). Methods: Premenopausal patients (pts) with ER+ and/or PgR+ ABC or RBC refractory to LH-RHa + TAM were treated with LH-RHa (goserelin: GOS) and AI (anastrozole: ANA). The primary endpoint was an objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR) based on RECIST, and safety assessed using CTCAE ver. 3.0. Pts with only bone legions were assessed using the criteria by Japanese Breast Cancer Society (14th Ed.). Local assessment (CR, PR or long SD of 24 weeks or longer) was confirmed independently by two radiologists. Results: Between September 2008 and November 2010, 37 pts were enrolled at 10 clinical institutions in Japan. Eleven had recurrence either during, or within one year after the end of adjuvant GOS + TAM (including GOS + TAM followed by only TAM). The disease progressed in 26 women during GOS + TAM. Mean age and BMI were 43.5 years and 22.2 kg/m2, respectively. Thirty-five pts (94.6%) were ER+, and 36 pts (97.3%) were HER2- (one with unknown HER2 status). Non-endocrine treatment included chemotherapy (20 pts; 54%) and radiation therapy (13 pts; 35%). The viscera, soft tissue, and bones were treated in 17, 15 and 14 pts, respectively. Pts with both measurable lesions and bone metastasis, measurable lesions only, and only bone metastasis were 21 (57%), 15 (41%) and 1 (2%), respectively. ORR was 18.9% (95%CI: 8.0-35.2%, 1 CR and 6 PR cases), CBR 62.2% (23 pts, 95%CI: 44.8-77.5%), and median PFS was 7.2 months. Eight pts (21.6%) had adverse events, but none resulted in treatment discontinuation. GOS + ANA was well tolerated. Conclusions: LH-RHa (GOS) + ANA can be a subsequent endocrine treatment for premenopausal pts with ABC or RBC after failure of GOS + TAM.

Recurrent Breast Cancer – Hyperbaric Oxygen Therapy

2020 ◽  
Vol 5 (5) ◽  
Keyword(s):  
Breast Cancer ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Recurrent Breast Cancer ◽  
Primary Diagnosis ◽  
Current Medical ◽  
Er Positive ◽  
Recurrent Breast ◽  
Positive Recurrent

Primary Diagnosis: Breast Cancer (2005). Past Treatment included Chemotherapy, Radiation Therapy. Current Medical: Recurrent Breast Cancer, Metastatic ER positive, Recurrent HER2 negative breast cancer, Oesophageal stricture. Currently taking Tamoxifen. * Referred for Hyperbaric Oxygen Therapy to assist her current medical management.

scholarly journals Recurrent Breast Cancer – Hyperbaric Oxygen Therapy

2020 ◽  
Vol 5 (5) ◽  
Keyword(s):  
Breast Cancer ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Recurrent Breast Cancer ◽  
Primary Diagnosis ◽  
Current Medical ◽  
Er Positive ◽  
Recurrent Breast ◽  
Positive Recurrent

Primary Diagnosis: Breast Cancer (2005). Past Treatment included Chemotherapy, Radiation Therapy. Current Medical: Recurrent Breast Cancer, Metastatic ER positive, Recurrent HER2 negative breast cancer, Oesophageal stricture. Currently taking Tamoxifen. * Referred for Hyperbaric Oxygen Therapy to assist her current medical management.

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

1996 ◽  
Vol 14 (9) ◽  
pp. 2584-2589 ◽  
Author(s):  
T Kuukasjärvi ◽  
J Kononen ◽  
H Helin ◽  
K Holli ◽  
J Isola
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Poor Response ◽  
Recurrent Breast Cancer ◽  
Hormone Receptor Status ◽  
Primary Tumors ◽  
Er Positive ◽  
Recurrent Breast ◽  
Er Expression

PURPOSE Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy. We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy. PATIENTS AND METHODS Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy. Estrogen receptor (ER) and progesterone receptor (PR) status was determined immunohistochemically from histologically representative formalin-fixed paraffin-embedded tumor samples. ER status was ascertained by mRNA in situ hybridization. RESULTS Thirty-five (70%) of 50 primary tumors were positive for ER and 30 (60%) for PR. Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%). Discordant cases were due to the loss of ER (n = 6), loss of PR (n = 6), or loss of both receptors (n = 6). Receptor-negative primary tumors were always accompanied by receptor-negative recurrences. Among 27 patients with ER-positive primary tumors, loss of ER was a significant predictor (P = .0085) of poor response to subsequent endocrine therapy. Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression. CONCLUSION Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients. We conclude that analysis of recurrent tumor samples may improve the predictive value of ER and PR assays.

Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study

2019 ◽  
Vol 195 (4) ◽  
pp. 318-326 ◽  
Author(s):  
C. De-Colle ◽  
N. Weidner ◽  
V. Heinrich ◽  
S. Brucker ◽  
M. Hahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Chest Wall ◽  
Prospective Observational Study ◽  
Recurrent Breast Cancer ◽  
Recurrent Breast

ER, PR & HER2 Receptor status in recurrent breast cancer: Its relation to age & time of recurrence

2020 ◽  
Vol 22 (1) ◽  
pp. 16-20
Author(s):  
Abu Khaled Muhammad Iqbal ◽  
Nasima Akhter ◽  
Hasan Shahrear Ahmed ◽  
Md Rassell ◽  
AMM Yahia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Approach ◽  
Recurrent Breast Cancer ◽  
Breast Cancer Patients ◽  
Her2 Receptor ◽  
Younger Patients ◽  
Receptor Status ◽  
Increased Risk ◽  
Neoplastic Lesions ◽  
Recurrent Breast

Background: Malignant neoplastic lesions of the breast are one of the main causes of cancer death among women. In tumor cells the expression status of Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers affecting the treatment approach, management and prognosis of breast carcinoma. Objective: To explore the relation of receptor status in recurrent breast cancer to age and time of recurrence. Methods: This study was conducted in National Institute of Cancer Research and Hospital (NICRH) and included 81 female patients between 20 to 75 years with recurrent breast cancer. Detection of receptor status of ER +ve/-ve, PR +ve/-ve, Her-2+ve/-ve was based on the immunohistochemistry staining of tissue samples of malignant neoplastic lesions prepared from tissue biopsies of patients with recurrent breast cancer. All the information were recorded through the pre-structured data collection sheet and analyzed. Results: This study showed that most of the recurrent breast cancer patients were Triple negative breast cancer (TNBC) (39.5%) and among them most of them were younger patients. Younger patients with TNBC had increased risk of recurrence. Most of the recurrence occurred within 1-2 years. Conclusion: It can be concluded that the assessment of the expression of these biornarkers in recurrent tumors provides reliable information for the treatment approach of locoregional tumors. Journal of Surgical Sciences (2018) Vol. 22 (1): 16-20

Sign in / Sign up

Export Citation Format

Share Document